OXiGENE Inc. (OXGN) Enters into Collaborative Agreement with National Cancer Institute for Cancer Drug
OXiGENE Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat cancer and eye diseases, has entered into a cooperative research and development agreement with the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP) to collaborate on the conduct of a randomized phase 2 trial of OXiGENE’s ZYBRESTAT in combination with bevacizumab in patients with relapsed ovarian cancer. The goal of the trial is to determine if ZYBRESTAT, in combination with bevacizumab, will enhance anti-tumor effects and delay progression of the tumor compared to results of bevacizumab alone. The agreement calls for OXiGENE to provide ZYBRESTAT to…